James Kasuboski

James Kasuboski is an accomplished professional in the field of biotechnology and health research, currently serving as Partner and Head of Research at Luma Group since January 2024, where the team is focused on advancing human health outcomes through innovative investments. In addition to this role, James serves as an Investor Member at the Advanced Research Projects Agency for Health (ARPA-H) and has held various advisory and board positions, including Grant Reviewer for the DR Ralph and Marian Falk Medical Research Trust and the National Cancer Institute. James co-founded Avilar Therapeutics and has been actively involved with organizations such as ReAx Biotechnologies and Glyphic Biotechnologies as a board member. With a Ph.D. in Molecular & Cellular Biology from the University of Notre Dame and a B.S. in Biology from Hillsdale College, James contributes extensive knowledge and experience to the biotech and research sectors.